1.Clinicopathological study on secretory meningioma
Fulin SONG ; Haiming QIN ; Wenchen HUANG
Chinese Journal of Practical Internal Medicine 2006;0(16):-
Objective To study the clinicopathological characteristics and ultrastructural features of secretory meningioma.Methods A total of 19 cases of secretory meningioma were studied by clinicopathology,immunohistochemical and ultrastructural observation.Results Eosinophilic hyaline inclusions with different sizes were found in cytoplasm of tumor cell,which were positive to PAS and alcian blue stains.These inclusions were secreted by microvesicles in cytoplasm of tumor cell under electron microscopy.Conclusion Immunohistochemistry and ultrastructural observation play important roles in the diagnosis and differential diagnosis of this tumor.
2.Advances in the treatment of spinal muscular atrophy
International Journal of Pediatrics 2024;51(2):119-123
Spinal muscular atrophy(SMA),an autosomal recessive genetic disease characterized by progressive weakness and atrophy of the proximal limbs caused by degeneration of motor neurons in the anterior horn of the spinal cord,can affect multiple systems such as respiratory,digestive,and skeletal systems. Untreated children with severe type 1 SMA usually die within 2 years of age. In recent years,the treatment of SMA has developed rapidly,and a variety of drugs have been approved to benefit patients. However,none of the existing therapeutic drugs or regimens can achieve a complete cure. Therefore,the combination of different therapeutic drugs and the research and development of new drugs may be the way forward for the treatment of SMA. The latest progress of therapeutic drugs and combination therapy in SMA are summarized in this review,which may be helpful for guiding the treatment of SMA.
3.Influences of the copy number of SMN2 and transcript level of fl-SMN2 on the phenotype and survival of spinal muscular atrophy
Shijia OUYANG ; Jinli BAI ; Yuwei JIN ; Hong WANG ; Wenchen HUANG ; Xiaoyin PENG ; Xiushan GE ; Hui JIAO ; Yujin QU ; Fang SONG
Chinese Journal of Applied Clinical Pediatrics 2023;38(11):863-868
Objective:To explore the distribution of the copy number of survival motor neuron gene 2 ( SMN2) and the transcript level of the full-length SMN2 ( fl-SMN2) transcript level in patients with type 1-3 spinal muscular atrophy (SMA), and to evaluate their influences on disease severity, progression, and prognosis. Methods:It was a retrospective study involving 78 therapy-naive SMA patients with SMN1 gene homozygous deletion who were diagnosed and treated in the Capital Institute of Pediatrics from January 2019 to December 2021.Cross-sectional clinical data, including age at onset, motor milestones, and complications were recorded.They were followed up for monitoring motor function degeneration and survival.The copy number of SMN2 and the transcript level of fl-SMN2 were detected.Differences between groups were compared by the Student′s t-test or One- Way ANOVA or Chi- square test.Kaplan-Meier analysis was used for survival analysis, and Kendall′ s tau- c was performed to assess the correlation of these two biomarkers with SMA phenotypes, age at onset, motor milestones, and survival. Results:Of the 78 SMA patients, there were 17 cases (21.8%) of type 1, 34 cases(43.6%) of type 2, and 27 cases(34.6%) of type 3.Seven cases(41.2%) type 1 SMA patients died, with a median survival time of 11 months, and no deaths were observed in type 2 and type 3 SMA patients.There was a significant difference in the median age at onset among SMA patients with 2, 3, and 4 copies of SMN2 (1.8, 12.0, and 24.0 months, respectively; F=4.943, P=0.01). The mean transcript level of fl-SMN2 in type 1, 2 and 3 SMA patients were 196.25±68.79, 331.21±108.79 and 455.69±122.27, respectively ( F=37.154, P<0.001). The survival rate of SMA with 2 SMN2 copies at 1, 2, and 5 years were 50.5%, 0, and 0, respectively, and their median survival age was 7 months.The survival rate of SMA with 3 and 4 SMN2 copies at 5 years were 97.4% and 100.0%, respectively.Moreover, a negative correlation was observed between the transcript level of fl-SMN2 and phenotype severity ( Kendall′ s tau- c=-0.444, P<0.001), and the transcript level of fl-SMN2 of the survival group was much higher than that of the death group (342.93±125.74 vs.212.14±92.31). More copies of SMN2 and higher transcript level of fl- SMN2 indicated more motor function acquisitions (head control, sitting and walking) ( P<0.001). In addition, there was a significant difference in the transcription level of fl-SMN2 between the undegenerated group and the degenerated group in sitting and standing ( F=5.432, P=0.023 and F=4.315, P=0.047, respectively). Conclusions:Both the copy number of SMN2 and the transcript level of fl-SMN2 are correlated with SMA severity, survival, and motor milestones, serving as valuable biomarkers for evaluating phenotypic severity of SMA.The transcript level of fl-SMN2 s may play an important role in the degeneration of sitting and standing.